Urogen Pharma Ltd
URGN18.870USD
+0.770+4.25%
收盘 09/18, 16:00（美东）报价延迟15分钟
871.78M总市值
亏损市盈率 TTM
关于 Urogen Pharma Ltd 公司
UroGen Pharma Ltd. 是一家位于以色列的生物制药公司。该公司致力于为癌症和泌尿系统疾病提供解决方案。UroGen 开发了 RTGelTM 逆向热凝胶，这是一种专有的缓释水凝胶平台技术，有可能改善现有药物的治疗效果。其主要候选产品包括 MitoGel 和 VesiGel，采用其专有的逆向热触发水凝胶或 RTGel 技术配制而成。MiroGel (UGN-101) 是化疗药物丝裂霉素 C 的缓释制剂，用于治疗低级别上尿路上皮癌，这是一种上尿路上皮癌。VesiGel (UGN-102) 是高剂量丝裂霉素 C 的缓释制剂，用于治疗低级别非肌层浸润性膀胱癌 (LG-NMIBC)。
公司简介
公司代码URGN
公司名称Urogen Pharma Ltd
上市日期May 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
员工数量235
证券类型Ordinary Share
年结日May 04
公司地址9 Ha'ta'asiya St
城市RA'ANANA
上市交易所NASDAQ Global Market Consolidated
国家Israel
邮编4365007
电话97297707601
网址https://www.urogen.com/
公司代码URGN
上市日期May 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
Jelmyto
20.25M
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
Jelmyto
20.25M
0.00%
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
其他
68.76%
持股股东
持股股东
占比
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
其他
68.76%
股东类型
持股股东
占比
Hedge Fund
29.41%
Research Firm
21.31%
Investment Advisor/Hedge Fund
20.23%
Investment Advisor
17.86%
Corporation
4.77%
Insurance Company
4.19%
Venture Capital
3.21%
Private Equity
2.11%
Individual Investor
2.09%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
2023Q1
221
19.00M
81.20%
-1.17M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RTW Investments L.P.
3.83M
8.32%
--
--
Mar 31, 2025
TD Securities, Inc.
2.65M
5.75%
+903.36K
+51.65%
Jun 09, 2025
Jefferies LLC
815.00K
1.77%
-150.93K
-15.63%
Mar 31, 2025
Soleus Capital Management, L.P.
2.33M
5.04%
+2.33M
--
Jun 13, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.65%
-50.01K
-2.28%
Mar 31, 2025
SilverArc Capital Management, LLC
1.38M
3%
+260.69K
+23.27%
Mar 31, 2025
Pontifax Venture Capital
1.49M
3.22%
-1.00
-0.00%
Mar 14, 2024
Arkin Communication, Ltd.
1.37M
2.97%
--
--
Feb 22, 2024
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
ARK Israel Innovative Technology ETF
2.21%
ALPS Medical Breakthroughs ETF
0.55%
Tema Oncology ETF
0.43%
Hypatia Women CEO ETF
0.21%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
Vanguard US Momentum Factor ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.07%
iShares Russell 2000 Growth ETF
0.04%
查看更多
ARK Israel Innovative Technology ETF
占比2.21%
ALPS Medical Breakthroughs ETF
占比0.55%
Tema Oncology ETF
占比0.43%
Hypatia Women CEO ETF
占比0.21%
iShares Micro-Cap ETF
占比0.16%
Invesco Nasdaq Biotechnology ETF
占比0.1%
Vanguard US Momentum Factor ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.09%
iShares Biotechnology ETF
占比0.07%
iShares Russell 2000 Growth ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
